In October 2022, a landmark workshop held in Ann Arbor included over 90 attendees, representing diverse backgrounds from around the globe. Participants included patients and representatives from leading biopharmaceutical, biotech, and medical device companies, JDRF, the National Institutes of Health, the American Diabetes Association, the US Food and Drug Administration, and other key stakeholders. Researchers and clinicians from the United States, Europe, Japan, Singapore, and Australia gathered to discuss various methods for improving the diagnosis of Diabetic Retinal Disease (DRD), with an emphasis on visual function and the importance of listening to patient voices.
Establishing biomarkers and clinical endpoints for DRD is a critical component of the Mary Tyler Moore Vision Initiative’s efforts. Our goal is to develop new methods for early diagnosis, assess disease severity and risk, and predict the rate of progression and response to therapy.
The workshop identified knowledge gaps in the field and the participants will continue to work in a public-private consortium to develop new endpoints for research and clinical care of patients with this condition – all to serve the overarching purpose of the Mary Tyler Moore Vision Initiative — to accelerate the development of new methods to preserve and restore vision and create a world without vision loss from diabetes.
Our Agenda:
